Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment

Autor: Kuniko Utsugi, Shuhei Okamoto, Kimihiko Sakamoto, Kohei Omatsu, Hidetaka Nomura, Nobuhiro Takeshima, Takeru Sugihara, Hiroyuki Kanao, Yoichi Aoki, Yuko Sugiyama, Kazuyoshi Kato, Maki Matoda, Terumi Tanigawa
Rok vydání: 2018
Předmět:
Adult
medicine.medical_specialty
Observational Study
chemotherapy
Gastroenterology
Drug Administration Schedule
oral leukoplakia
Polyethylene Glycols
03 medical and health sciences
0302 clinical medicine
pegylated liposomal doxorubicin
stomatognathic system
Tongue
Risk Factors
Internal medicine
Mucositis
medicine
Humans
Risk factor
Leukoplakia
Aged
Retrospective Studies
secondary cancer
Aged
80 and over
Ovarian Neoplasms
Univariate analysis
Antibiotics
Antineoplastic
Cumulative dose
business.industry
Incidence (epidemiology)
General Medicine
Middle Aged
medicine.disease
stomatognathic diseases
medicine.anatomical_structure
Doxorubicin
030220 oncology & carcinogenesis
lipids (amino acids
peptides
and proteins)
Female
Leukoplakia
Oral
business
Ovarian cancer
030217 neurology & neurosurgery
Research Article
Zdroj: Medicine
ISSN: 1536-5964
Popis: Pegylated liposomal doxorubicin (PLD) has a good safety profile, but long-term use has been associated with development of squamous cell carcinoma of the tongue and oral cavity (SCCTO) in some patients. The study objective was to estimate the prevalence of oral leukoplakia, a known precursor of SCCTO, in patients with ovarian cancer and long-term PLD use. After approval of the institutional review board, medical record of 114 patients who were treated with PLD at our institution between January 2010 and December 2016 were retrospectively reviewed. All those patients have been referred for routine monitoring of oral mucositis every time before administration by a dentist. The patient characteristics included in the evaluation were age, smoking and drinking habits, the PLD dose and schedule, and presence or absence of oral leukoplakia and SCCTO at each oral examination. The relationships of the incidence of oral leukoplakia and patient characteristics were analyzed. The median total PLD dose was 160 (range 40–1550) mg/m2. Oral leukoplakia was seen in 6 (5.3%) patients. The median PLD dose, at the time of oral leukoplakia diagnosis, was 685 (range 400–800) mg/m2. SCCTO was not found. Univariate analysis revealed that age, Brinkman index, and habitual drinking were not considered as risk factors for oral leukoplakia, and only total PLD dose (OR, 1.470; 95% CI, 1.19–1.91; P
Databáze: OpenAIRE
Externí odkaz: